The Serum Institute of India, the world’s biggest vaccine maker, let Africa down by pulling out of addresses to supply COVID-19 vaccines, creating mistrust that has affected demand, according to the head of the Africa Centres for Disease Control.
John Nkengasong on Thursday denounced recent commentary from Serum that uptake of its COVID-19 shots had braked because of low demand from Africa and vaccine hesitancy, saying the real problem was that Serum had acted unprofessionally.
Nkengasong said Serum had engaged in conversations last time with the Africa Vaccine Acquisition Task Team (AVATT), and that at one point he’d believed a deal was veritably near, but also Serum suddenly ended the addresses.
“ Serum just decided to act in a veritably unskillful manner and stop communicating with AVATT platoon, so that created a situation where we plant ourselves extremely unhappy … and also engaged with Johnson & Johnson,” he said.
African countries had agreed to buy 400 million boluses of COVID vaccines from J&J, abandoning sweats with Serum, he said.
Also, before in 2021 came India’s decision to ban vaccine exports as domestic infections soared, which had created farther mistrust abroad, and that explained the lack of demand from Africa for Serum’s vaccines, Nkengasong said.
Still, I do n’t know the mechanics of what volumes they’re dispatching to COVAX, but it’ll not surprise me that countries are now looking at that (thinking)‘OK, “ If now Serum is dispatching vaccines to COVAX.
Global vaccine- participating network COVAX is still seeing strong demand for Serum’s AstraZeneca shot, one of its backers GAVI said on Thursday, following commentary from Serum that uptake had braked.